SCOPUS 정보 검색 플랫폼

Journal of Experimental Medicine

Volumn 213, Issue 13, 2016, Pages 2835-2840

What does PD-L1 positive or negative mean?

(2) Ribas, Antoni a,b Hu Lieskovan, Siwen a,b

a UNIVERSITY OF CALIFORNIA (United States)

b UNIVERSITY OF CALIFORNIA (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

ARTICLE; HUMAN; LOSS OF FUNCTION MUTATION; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; T LYMPHOCYTE; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIGENS, CD274; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85008428512 PISSN: 00221007 EISSN: 15409538 Source Type: Journal
DOI: 10.1084/jem.20161462 Document Type: Article

Times cited : (265)

References (47)

1
- 84890020587
- Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
- Akbay, E.A., S. Koyama, J. Carretero, A. Altabef, J.H. Tchaicha, C.L. Christensen, O.R. Mikse, A.D. Cherniack, E.M. Beauchamp, T.J. Pugh, et al. 2013. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3:1355-1363. http://dx.doi.org/10.1158/2159-8290.CD-13-0310
- (2013) Cancer Discov , vol.3 , pp. 1355-1363
- Akbay, E.A.¹ Koyama, S.² Carretero, J.³ Altabef, A.⁴ Tchaicha, J.H.⁵ Christensen, C.L.⁶ Mikse, O.R.⁷ Cherniack, A.D.⁸ Beauchamp, E.M.⁹ Pugh, T.J.¹⁰

2
- 84925221855
- PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
- Ansell, S.M., A.M. Lesokhin, I. Borrello, A. Halwani, E.C. Scott, M. Gutierrez, S.J. Schuster, M.M. Millenson, D. Cattry, G.J. Freeman, et al. 2015. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372:311-319. http://dx.doi.org/10.1056/NEJMoa1411087
- (2015) N. Engl. J. Med , vol.372 , pp. 311-319
- Ansell, S.M.¹ Lesokhin, A.M.² Borrello, I.³ Halwani, A.⁴ Scott, E.C.⁵ Gutierrez, M.⁶ Schuster, S.J.⁷ Millenson, M.M.⁸ Cattry, D.⁹ Freeman, G.J.¹⁰

3
- 0842325739
- + T cells
- + T cells. Cancer Res. 64:1140-1145. http://dx.doi.org/10.1158/0008-5472.CAN-03-3259
- (2004) Cancer Res , vol.64 , pp. 1140-1145
- Blank, C.¹ Brown, I.² Peterson, A.C.³ Spiotto, M.⁴ Iwai, Y.⁵ Honjo, T.⁶ Gajewski, T.F.⁷

4
- 84960842480
- MYC regulates the antitumor immune response through CD47 and PD-L1
- Casey, S.C., L. Tong, Y. Li, R. Do, S. Walz, K.N. Fitzgerald, A.M. Gouw, V. Baylot, I. Gütgemann, M. Eilers, and D.W. Felsher. 2016. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 352:227-231. http://dx.doi.org/10.1126/science.aac9935
- (2016) Science , vol.352 , pp. 227-231
- Casey, S.C.¹ Tong, L.² Li, Y.³ Do, R.⁴ Walz, S.⁵ Fitzgerald, K.N.⁶ Gouw, A.M.⁷ Baylot, V.⁸ Gütgemann, I.⁹ Eilers, M.¹⁰ Felsher, D.W.¹¹

5
- 84902825664
- Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients
- Cha, E., M. Klinger, Y. Hou, C. Cummings, A. Ribas, M. Faham, and L. Fong. 2014. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6:238ra70. http://dx.doi.org/10.1126/scitranslmed.3008211
- (2014) Sci. Transl. Med , vol.6
- Cha, E.¹ Klinger, M.² Hou, Y.³ Cummings, C.⁴ Ribas, A.⁵ Faham, M.⁶ Fong, L.⁷

6
- 84979502955
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- Dorand, R.D., J. Nthale, J.T. Myers, D.S. Barkauskas, S. Avril, S.M. Chirieleison, T.K. Pareek, D.W. Abbott, D.S. Stearns, J.J. Letterio, et al. 2016. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 353:399-403. http://dx.doi.org/10.1126/science.aae0477
- (2016) Science , vol.353 , pp. 399-403
- Dorand, R.D.¹ Nthale, J.² Myers, J.T.³ Barkauskas, D.S.⁴ Avril, S.⁵ Chirieleison, S.M.⁶ Pareek, T.K.⁷ Abbott, D.W.⁸ Stearns, D.S.⁹ Letterio, J.J.¹⁰

7
- 17144365840
- IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression
- Dunn, G.P., K.C. Sheehan, L.J. Old, and R.D. Schreiber. 2005. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65:3447-3453. http://dx.doi.org/10.1158/0008-5472.CAN-04-4316
- (2005) Cancer Res , vol.65 , pp. 3447-3453
- Dunn, G.P.¹ Sheehan, K.C.² Old, L.J.³ Schreiber, R.D.⁴

8
- 84929481480
- Pembrolizumab for the treatment of non-small-cell lung cancer
- Garon, E.B., N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, et al. KEY NOTE-001 Investigators. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372:2018-2028. http://dx.doi.org/10.1056/NEJMoa1501824
- (2015) N. Engl. J. Med , vol.372 , pp. 2018-2028
- Garon, E.B.¹ Rizvi, N.A.² Hui, R.³ Leighl, N.⁴ Balmanoukian, A.S.⁵ Eder, J.P.⁶ Patnaik, A.⁷ Aggarwal, C.⁸ Gubens, M.⁹ Horn, L.¹⁰

9
- 78049370405
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- Green, M.R., S. Monti, S.J. Rodig, P. Juszczynski, T. Currie, E. O'Donnell, B. Chapuy, K. Takeyama, D. Neuberg, T.R. Golub, et al. 2010. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 116:3268-3277. http://dx.doi.org/10.1182/blood-2010-05-282780
- (2010) Blood , vol.116 , pp. 3268-3277
- Green, M.R.¹ Monti, S.² Rodig, S.J.³ Juszczynski, P.⁴ Currie, T.⁵ O'Donnell, E.⁶ Chapuy, B.⁷ Takeyama, K.⁸ Neuberg, D.⁹ Golub, T.R.¹⁰

10
- 84920956735
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Herbst, R.S., J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563-567. http://dx.doi.org/10.1038/nature14011
- (2014) Nature , vol.515 , pp. 563-567
- Herbst, R.S.¹ Soria, J.C.² Kowanetz, M.³ Fine, G.D.⁴ Hamid, O.⁵ Gordon, M.S.⁶ Sosman, J.A.⁷ McDermott, D.F.⁸ Powderly, J.D.⁹ Gettinger, S.N.¹⁰

11
- 79959206459
- CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans
- Huang, R.R., J. Jalil, J.S. Economou, B. Chmielowski, R.C. Koya, S. Mok, H. Sazegar, E. Seja, A. Villanueva, J. Gomez-Navarro, et al. 2011. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 17:4101-4109. http://dx.doi.org/10.1158/1078-0432.CCR-11-0407
- (2011) Clin. Cancer Res , vol.17 , pp. 4101-4109
- Huang, R.R.¹ Jalil, J.² Economou, J.S.³ Chmielowski, B.⁴ Koya, R.C.⁵ Mok, S.⁶ Sazegar, H.⁷ Seja, E.⁸ Villanueva, A.⁹ Gomez-Navarro, J.¹⁰

12
- 84964858970
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
- Ilie, M., V. Hofman, M. Dietel, J.C. Soria, and P. Hofman. 2016. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 468:511-525. http://dx.doi.org/10.1007/s00428-016-1910-4
- (2016) Virchows Arch , vol.468 , pp. 511-525
- Ilie, M.¹ Hofman, V.² Dietel, M.³ Soria, J.C.⁴ Hofman, P.⁵

13
- 34548740090
- The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
- Juszczynski, P., J. Ouyang, S. Monti, S.J. Rodig, K. Takeyama, J. Abramson, W. Chen, J.L. Kutok, G.A. Rabinovich, and M.A. Shipp. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA. 104:13134-13139. http://dx.doi.org/10.1073/pnas.0706017104
- (2007) Proc. Natl. Acad. Sci. USA , vol.104 , pp. 13134-13139
- Juszczynski, P.¹ Ouyang, J.² Monti, S.³ Rodig, S.J.⁴ Takeyama, K.⁵ Abramson, J.⁶ Chen, W.⁷ Kutok, J.L.⁸ Rabinovich, G.A.⁹ Shipp, M.A.¹⁰

14
- 0032560475
- Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
- Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and R.D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95:7556-7561. http://dx.doi.org/10.1073/pnas.95.13.7556
- (1998) Proc. Natl. Acad. Sci. USA , vol.95 , pp. 7556-7561
- Kaplan, D.H.¹ Shankaran, V.² Dighe, A.S.³ Stockert, E.⁴ Aguet, M.⁵ Old, L.J.⁶ Schreiber, R.D.⁷

15
- 84973131266
- Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
- Kataoka, K., Y. Shiraishi, Y. Takeda, S. Sakata, M. Matsumoto, S. Nagano, T. Maeda, Y. Nagata, A. Kitanaka, S. Mizuno, et al. 2016. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature. 534:402-406. http://dx.doi.org/10.1038/nature18294
- (2016) Nature , vol.534 , pp. 402-406
- Kataoka, K.¹ Shiraishi, Y.² Takeda, Y.³ Sakata, S.⁴ Matsumoto, M.⁵ Nagano, S.⁶ Maeda, T.⁷ Nagata, Y.⁸ Kitanaka, A.⁹ Mizuno, S.¹⁰

16
- 24344488326
- Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells
- Kim, J., A.C. Myers, L. Chen, D.M. Pardoll, Q.A. Truong-Tran, A.P. Lane, J.F. McDyer, L. Fortuno, and R.P. Schleimer. 2005. Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 33:280-289. http://dx.doi.org/10.1165/rcmb.2004-0129OC
- (2005) Am. J. Respir. Cell Mol. Biol , vol.33 , pp. 280-289
- Kim, J.¹ Myers, A.C.² Chen, L.³ Pardoll, D.M.⁴ Truong-Tran, Q.A.⁵ Lane, A.P.⁶ McDyer, J.F.⁷ Fortuno, L.⁸ Schleimer, R.P.⁹

17
- 84936147067
- Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
- Larkin, J., V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23-34. http://dx.doi.org/10.1056/NEJMoa1504030
- (2015) N. Engl. J. Med , vol.373 , pp. 23-34
- Larkin, J.¹ Chiarion-Sileni, V.² Gonzalez, R.³ Grob, J.J.⁴ Cowey, C.L.⁵ Lao, C.D.⁶ Schadendorf, D.⁷ Dummer, R.⁸ Smylie, M.⁹ Rutkowski, P.¹⁰

18
- 84958963164
- Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer
- Lastwika, K.J., W. Wilson III, Q.K. Li, J. Norris, H. Xu, S.R. Ghazarian, H. Kitagawa, S. Kawabata, J.M. Taube, S. Yao, et al. 2016. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 76:227-238. http://dx.doi.org/10.1158/0008-5472.CAN-14-3362
- (2016) Cancer Res , vol.76 , pp. 227-238
- Lastwika, K.J.¹ Wilson, W.² Li, Q.K.³ Norris, J.⁴ Xu, H.⁵ Ghazarian, S.R.⁶ Kitagawa, H.⁷ Kawabata, S.⁸ Taube, J.M.⁹ Yao, S.¹⁰

19
- 31444451661
- Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
- Lee, S.J., B.C. Jang, S.W. Lee, Y.I. Yang, S.I. Suh, Y.M. Park, S. Oh, J.G. Shin, S. Yao, L. Chen, and I.H. Choi. 2006. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580:755-762. http://dx.doi.org/10.1016/j.febslet.2005.12.093
- (2006) FEBS Lett , vol.580 , pp. 755-762
- Lee, S.J.¹ Jang, B.C.² Lee, S.W.³ Yang, Y.I.⁴ Suh, S.I.⁵ Park, Y.M.⁶ Oh, S.⁷ Shin, J.G.⁸ Yao, S.⁹ Chen, L.¹⁰ Choi, I.H.¹¹

20
- 0242303572
- Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
- Liang, S.C., Y.E. Latchman, J.E. Buhlmann, M.F. Tomczak, B.H. Horwitz, G.J. Freeman, and A.H. Sharpe. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706-2716. http://dx.doi.org/10.1002/eji.200324228
- (2003) Eur. J. Immunol , vol.33 , pp. 2706-2716
- Liang, S.C.¹ Latchman, Y.E.² Buhlmann, J.E.³ Tomczak, M.F.⁴ Horwitz, B.H.⁵ Freeman, G.J.⁶ Sharpe, A.H.⁷

21
- 0038302927
- PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
- Loke, P., and J.P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA. 100:5336-5341. http://dx.doi.org/10.1073/pnas.0931259100
- (2003) Proc. Natl. Acad. Sci. USA , vol.100 , pp. 5336-5341
- Loke, P.¹ Allison, J.P.²

22
- 0037925143
- Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNγ-induced apoptosis
- Mazzolini, G., I. Narvaiza, L.A. Martinez-Cruz, A. Arina, M. Barajas, J.C. Galofré, C. Qian, J.M. Mato, J. Prieto, and I. Melero. 2003. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNγ-induced apoptosis. Gene Ther. 10:1067-1078. http://dx.doi.org/10.1038/sj.gt.3301957
- (2003) Gene Ther , vol.10 , pp. 1067-1078
- Mazzolini, G.¹ Narvaiza, I.² Martinez-Cruz, L.A.³ Arina, A.⁴ Barajas, M.⁵ Galofré, J.C.⁶ Qian, C.⁷ Mato, J.M.⁸ Prieto, J.⁹ Melero, I.¹⁰

23
- 84962497081
- Atezolizumab, an anti-Programmed Death-Ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study
- McDermott, D.F., J.A. Sosman, M. Sznol, C. Massard, M.S. Gordon, O. Hamid, J.D. Powderly, J.R. Infante, M. Fassò, Y.V. Wang, et al. 2016. Atezolizumab, an anti-Programmed Death-Ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34:833-842. http://dx.doi.org/10.1200/JCO.2015.63.7421
- (2016) J. Clin. Oncol , vol.34 , pp. 833-842
- McDermott, D.F.¹ Sosman, J.A.² Sznol, M.³ Massard, C.⁴ Gordon, M.S.⁵ Hamid, O.⁶ Powderly, J.D.⁷ Infante, J.R.⁸ Fassò, M.⁹ Wang, Y.V.¹⁰

24
- 84976511909
- PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma
- Nghiem, P.T., S. Bhatia, E.J. Lipson, R.R. Kudchadkar, N.J. Miller, L. Annamalai, S. Berry, E.K. Chartash, A. Daud, S.P. Fling, et al. 2016. PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374:2542-2552. http://dx.doi.org/10.1056/NEJMoa1603702
- (2016) N. Engl. J. Med , vol.374 , pp. 2542-2552
- Nghiem, P.T.¹ Bhatia, S.² Lipson, E.J.³ Kudchadkar, R.R.⁴ Miller, N.J.⁵ Annamalai, L.⁶ Berry, S.⁷ Chartash, E.K.⁸ Daud, A.⁹ Fling, S.P.¹⁰

25
- 84968627725
- Pan-Cancer Immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration
- Ock, C.Y., B. Keam, S. Kim, J.S. Lee, M. Kim, T.M. Kim, Y.K. Jeon, D.W. Kim, D.H. Chung, and D.S. Heo. 2016. Pan-Cancer Immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin. Cancer Res. 22:2261-2270. http://dx.doi.org/10.1158/1078-0432.CCR-15-2834
- (2016) Clin. Cancer Res , vol.22 , pp. 2261-2270
- Ock, C.Y.¹ Keam, B.² Kim, S.³ Lee, J.S.⁴ Kim, M.⁵ Kim, T.M.⁶ Jeon, Y.K.⁷ Kim, D.W.⁸ Chung, D.H.⁹ Heo, D.S.¹⁰

26
- 84858766182
- The blockade of immune checkpoints in cancer immunotherapy
- Pardoll, D.M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12:252-264. http://dx.doi.org/10.1038/nrc3239
- (2012) Nat. Rev. Cancer , vol.12 , pp. 252-264
- Pardoll, D.M.¹

27
- 33846118474
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
- Parsa, A.T., J.S. Waldron, A. Panner, C.A. Crane, I.F. Parney, J.J. Barry, K.E. Cachola, J.C. Murray, T. Tihan, M.C. Jensen, et al. 2007. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13:84-88. http://dx.doi.org/10.1038/nm1517
- (2007) Nat. Med , vol.13 , pp. 84-88
- Parsa, A.T.¹ Waldron, J.S.² Panner, A.³ Crane, C.A.⁴ Parney, I.F.⁵ Barry, J.J.⁶ Cachola, K.E.⁷ Murray, J.C.⁸ Tihan, T.⁹ Jensen, M.C.¹⁰

28
- 85008513373
- Postow, M.A., J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, D. McDermott, G.P. Linette, N. Meyer, J.K. Giguere, S.S. Agarwala, et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melan/NEJMoa1414428
- (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melan/NEJMoa1414428
- Postow, M.A.¹ Chesney, J.² Pavlick, A.C.³ Robert, C.⁴ Grossmann, K.⁵ McDermott, D.⁶ Linette, G.P.⁷ Meyer, N.⁸ Giguere, J.K.⁹ Agarwala, S.S.¹⁰

29
- 84923078390
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Powles, T., J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H.A. Burris, D.P. Petrylak, S.L. Teng, et al. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558-562. http://dx.doi.org/10.1038/nature13904
- (2014) Nature , vol.515 , pp. 558-562
- Powles, T.¹ Eder, J.P.² Fine, G.D.³ Braiteh, F.S.⁴ Loriot, Y.⁵ Cruz, C.⁶ Bellmunt, J.⁷ Burris, H.A.⁸ Petrylak, D.P.⁹ Teng, S.L.¹⁰

30
- 84994802263
- Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
- Reck, M., D. Rodríguez-Abreu, A.G. Robinson, R. Hui, T. Csoszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, et al. KEY NOTE-024 Investigators. 2016. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375:1823-1833. http://dx.doi.org/10.1056/NEJMoa1606774
- (2016) N. Engl. J. Med , vol.375 , pp. 1823-1833
- Reck, M.¹ Rodríguez-Abreu, D.² Robinson, A.G.³ Hui, R.⁴ Csoszi, T.⁵ Fülöp, A.⁶ Gottfried, M.⁷ Peled, N.⁸ Tafreshi, A.⁹ Cuffe, S.¹⁰

31
- 84941800472
- Adaptive immune resistance: How cancer protects from immune attack
- Ribas, A. 2015. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov. 5:915-919. http://dx.doi.org/10.1158/2159-8290.CD-15-0563
- (2015) Cancer Discov , vol.5 , pp. 915-919
- Ribas, A.¹

32
- 84908405833
- The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade
- Ribas, A., and P.C. Tumeh. 2014. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin. Cancer Res. 20:4982-4984. http://dx.doi.org/10.1158/1078-0432.CCR-14-0933
- (2014) Clin. Cancer Res , vol.20 , pp. 4982-4984
- Ribas, A.¹ Tumeh, P.C.²

33
- 84964341647
- Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma
- Ribas, A., O. Hamid, A. Daud, F.S. Hodi, J.D. Wolchok, R. Kefford, A.M. Joshua, A. Patnaik, W.J. Hwu, J.S. Weber, et al. 2016. Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 315:1600-1609. http://dx.doi.org/10.1001/jama.2016.4059
- (2016) JAMA , vol.315 , pp. 1600-1609
- Ribas, A.¹ Hamid, O.² Daud, A.³ Hodi, F.S.⁴ Wolchok, J.D.⁵ Kefford, R.⁶ Joshua, A.M.⁷ Patnaik, A.⁸ Hwu, W.J.⁹ Weber, J.S.¹⁰

34
- 84925222119
- Nivolumab in previously untreated melanoma without BRAF mutation
- Robert, C., G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J.C. Hassel, P. Rutkowski, C. McNeil, E. Kalinka-Warzocha, et al. 2015a. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320-330. http://dx.doi.org/10.1056/NEJMoa1412082
- (2015) N. Engl. J. Med , vol.372 , pp. 320-330
- Robert, C.¹ Long, G.V.² Brady, B.³ Dutriaux, C.⁴ Maio, M.⁵ Mortier, L.⁶ Hassel, J.C.⁷ Rutkowski, P.⁸ McNeil, C.⁹ Kalinka-Warzocha, E.¹⁰

35
- 84929481481
- Pembrolizumab versus ipilimumab in advanced melanoma
- Robert, C., J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, A. Daud, M.S. Carlino, C. McNeil, M. Lotem, et al. KEY NOTE-006 investigators. 2015b. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:2521-2532. http://dx.doi.org/10.1056/NEJMoa1503093
- (2015) N. Engl. J. Med , vol.372 , pp. 2521-2532
- Robert, C.¹ Schachter, J.² Long, G.V.³ Arance, A.⁴ Grob, J.J.⁵ Mortier, L.⁶ Daud, A.⁷ Carlino, M.S.⁸ McNeil, C.⁹ Lotem, M.¹⁰

36
- 84899750907
- CTLA4 blockade broadens the peripheral T-cell receptor repertoire
- Robert, L., J. Tsoi, X. Wang, R. Emerson, B. Homet, T. Chodon, S. Mok, R.R. Huang, A.J. Cochran, B. Comin-Anduix, et al. 2014. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20:2424-2432. http://dx.doi.org/10.1158/1078-0432.CCR-13-2648
- (2014) Clin. Cancer Res , vol.20 , pp. 2424-2432
- Robert, L.¹ Tsoi, J.² Wang, X.³ Emerson, R.⁴ Homet, B.⁵ Chodon, T.⁶ Mok, S.⁷ Huang, R.R.⁸ Cochran, A.J.⁹ Comin-Anduix, B.¹⁰

37
- 84920962202
- Molecular and genetic properties of tumors associated with local immune cytolytic activity
- Rooney, M.S., S.A. Shukla, C.J. Wu, G. Getz, and N. Hacohen. 2015. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160:48-61. http://dx.doi.org/10.1016/j.cell.2014.12.033
- (2015) Cell , vol.160 , pp. 48-61
- Rooney, M.S.¹ Shukla, S.A.² Wu, C.J.³ Getz, G.⁴ Hacohen, N.⁵

38
- 85011827059
- Primary resistance to PD-1 blockade mediated by JAK1/2 mutations
- Shin, D.S., J.M. Zaretsky, H. Escuin-Ordinas, A. Garcia-Diaz, S. Hu-Lieskovan, A. Kalbasi, C.S. Grasso, W. Hugo, S. Sandoval, D.Y. Torrejon, et al. 2016. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-16-1223
- (2016) Cancer Discov
- Shin, D.S.¹ Zaretsky, J.M.² Escuin-Ordinas, H.³ Garcia-Diaz, A.⁴ Hu-Lieskovan, S.⁵ Kalbasi, A.⁶ Grasso, C.S.⁷ Hugo, W.⁸ Sandoval, S.⁹ Torrejon, D.Y.¹⁰

39
- 84874869077
- Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer
- Sznol, M., and L. Chen. 2013. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19:1021-1034. http://dx.doi.org/10.1158/1078-0432.CCR-12-2063
- (2013) Clin. Cancer Res , vol.19 , pp. 1021-1034
- Sznol, M.¹ Chen, L.²

40
- 84859128199
- Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
- Taube, J.M., R.A. Anders, G.D. Young, H. Xu, R. Sharma, T.L. McMiller, S. Chen, A.P. Klein, D.M. Pardoll, S.L. Topalian, and L. Chen. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4:127ra37. http://dx.doi.org/10.1126/scitranslmed.3003689
- (2012) Sci. Transl. Med , vol.4
- Taube, J.M.¹ Anders, R.A.² Young, G.D.³ Xu, H.⁴ Sharma, R.⁵ McMiller, T.L.⁶ Chen, S.⁷ Klein, A.P.⁸ Pardoll, D.M.⁹ Topalian, S.L.¹⁰ Chen, L.¹¹

41
- 84941797037
- Classifying cancers based on T-cell infiltration and PD-L1
- Teng, M.W., S.F. Ngiow, A. Ribas, and M.J. Smyth. 2015. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75:2139-2145. http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
- (2015) Cancer Res , vol.75 , pp. 2139-2145
- Teng, M.W.¹ Ngiow, S.F.² Ribas, A.³ Smyth, M.J.⁴

42
- 84862859820
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
- Topalian, S.L., F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454. http://dx.doi.org/10.1056/NEJMoa1200690
- (2012) N. Engl. J. Med , vol.366 , pp. 2443-2454
- Topalian, S.L.¹ Hodi, F.S.² Brahmer, J.R.³ Gettinger, S.N.⁴ Smith, D.C.⁵ McDermott, D.F.⁶ Powderly, J.D.⁷ Carvajal, R.D.⁸ Sosman, J.A.⁹ Atkins, M.B.¹⁰

43
- 84920956732
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Tumeh, P.C., C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568-571. http://dx.doi.org/10.1038/nature13954
- (2014) Nature , vol.515 , pp. 568-571
- Tumeh, P.C.¹ Harview, C.L.² Yearley, J.H.³ Shintaku, I.P.⁴ Taylor, E.J.⁵ Robert, L.⁶ Chmielowski, B.⁷ Spasic, M.⁸ Henry, G.⁹ Ciobanu, V.¹⁰

44
- 84931083080
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Weber, J.S., S.P. D'Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N.I. Khushalani, W.H. Miller Jr., C.D. Lao, et al. 2015. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375-384. http://dx.doi.org/10.1016/S1470-2045(15)70076-8
- (2015) Lancet Oncol , vol.16 , pp. 375-384
- Weber, J.S.¹ D'Angelo, S.P.² Minor, D.³ Hodi, F.S.⁴ Gutzmer, R.⁵ Neyns, B.⁶ Hoeller, C.⁷ Khushalani, N.I.⁸ Miller, W.H.⁹ Lao, C.D.¹⁰

45
- 84991110530
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an openlabel, randomised, phase 2 trial
- Weber, J.S., G. Gibney, R.J. Sullivan, J.A. Sosman, C.L. Slingluff Jr., D.P. Lawrence, T.F. Logan, L.M. Schuchter, S. Nair, L. Fecher, et al. 2016. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an openlabel, randomised, phase 2 trial. Lancet Oncol. 17:943-955. http://dx.doi.org/10.1016/S1470-2045(16)30126-7
- (2016) Lancet Oncol , vol.17 , pp. 943-955
- Weber, J.S.¹ Gibney, G.² Sullivan, R.J.³ Sosman, J.A.⁴ Slingluff, C.L.⁵ Lawrence, D.P.⁶ Logan, T.F.⁷ Schuchter, L.M.⁸ Nair, S.⁹ Fecher, L.¹⁰

46
- 84879777241
- Nivolumab plus ipilimumab in advanced melanoma
- Wolchok, J.D., H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, N.H. Segal, C.E. Ariyan, R.A. Gordon, K. Reed, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122-133. http://dx.doi.org/10.1056/NEJMoa1302369
- (2013) N. Engl. J. Med , vol.369 , pp. 122-133
- Wolchok, J.D.¹ Kluger, H.² Callahan, M.K.³ Postow, M.A.⁴ Rizvi, N.A.⁵ Lesokhin, A.M.⁶ Segal, N.H.⁷ Ariyan, C.E.⁸ Gordon, R.A.⁹ Reed, K.¹⁰

47
- 84983216790
- Mutations associated with acquired resistance to PD-1 blockade in melanoma
- Zaretsky, J.M., A. Garcia-Diaz, D.S. Shin, H. Escuin-Ordinas, W. Hugo, S. Hu-Lieskovan, D.Y. Torrejon, G. Abril-Rodriguez, S. Sandoval, L. Barthly, et al. 2016. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375:819-829. http://dx.doi.org/10.1056/NEJMoa1604958
- (2016) N. Engl. J. Med , vol.375 , pp. 819-829
- Zaretsky, J.M.¹ Garcia-Diaz, A.² Shin, D.S.³ Escuin-Ordinas, H.⁴ Hugo, W.⁵ Hu-Lieskovan, S.⁶ Torrejon, D.Y.⁷ Abril-Rodriguez, G.⁸ Sandoval, S.⁹ Barthly, L.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.